Overview

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

Status:
Terminated
Trial end date:
2012-08-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease). There is currently no alternative therapy available for this condition other than treatment with steroids, or radiotherapy and surgery. The study also includes a comparison of the current steroid treatment, methylprednisolone, with the proposed new otelixizumab treatment.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate